These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 6409615

  • 21. Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa.
    Prout GR, Koontz WW, Coombs LJ, Hawkins IR, Friedell GH.
    J Urol; 1983 Oct; 130(4):677-80. PubMed ID: 6411939
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Chemoprophylaxis with intravesical thiotepa in non-infiltrating bladder tumors].
    Lancina Martín J, Monsalve Rodríguez M, Gómez Cisneros S, García Alonso J.
    Arch Esp Urol; 1986 Sep; 39(7):479-83. PubMed ID: 3099658
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Use of intravesical thiotepa in superficial bladder tumours.
    Kulkarni JN, Kamat MR, Juvekar RL.
    Indian J Cancer; 1981 Sep; 18(3):222-4. PubMed ID: 6796504
    [No Abstract] [Full Text] [Related]

  • 30. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
    Zincke H, Benson RC, Hilton JF, Taylor WF.
    J Urol; 1985 Dec; 134(6):1110-4. PubMed ID: 3932685
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma.
    Burnand KG, Boyd PJ, Mayo ME, Shuttleworth KE, Lloyd-Davies RW.
    Br J Urol; 1976 Feb; 48(1):55-9. PubMed ID: 817761
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS, Chow NH, Lin JS, Yang WH, Tong YC.
    Anticancer Res; 1998 Feb; 18(6B):4717-21. PubMed ID: 9891547
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Intravesical and systemic chemotherapy in the management of superficial bladder cancer.
    Soloway MS.
    Urol Clin North Am; 1984 Nov; 11(4):623-35. PubMed ID: 6438857
    [Abstract] [Full Text] [Related]

  • 40. Intravesical thio-tepa in the immediate postoperative period in patients with recurrent transitional cell carcinoma of the bladder.
    Gavrell GJ, Lewis RW, Meehan WL, Leblanc GA.
    J Urol; 1978 Oct; 120(4):410-1. PubMed ID: 100615
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.